Introduction: The detection of anti-HCV antibodies is based on the use of third generation Enzyme Immunoassay (EIA) that detects antibodies directed against various HCV epitopes. HCV TRI-DOT test is a rapid, protein A immunofiltration assay for the qualitative detection of anti HCV antibodies in serum or plasma with a sensitivity of 100% and specificity of 91.5%. The study was conducted to compare the efficacy between 3rd generation ELISA and 4th generation TRI-DOT test to detect the seroprevalence of HCV and to assess the risk factors associated with HCV infection in the patients who are on haemodialysis.
INTRODUCTION
Any infection that results in inflammation of liver is called hepatitis. Though Hepatitis B is the commonest type of transfusion associated hepatitis but the incidence of Hepatitis C is increasing day by day. The prevalence of hepatitis C virus (HCV) infection worldwide is 3% and the 1 infected people are estimated at 170 millions. The prevalence of HCV among dialysis patients varies worldwide, ranging from as low as 1% to as high as over 2, 3 70% . The detection of anti-HCV antibodies is based on the use of third generation Enzyme Immunoassay (EIA) that detects antibodies directed against various HCV epitopes. EIA tests are reproducible, inexpensive, and suitable for use in the diagnosis of HCV infection. Given the good performance of third-generation EIA tests, immunoblot tests have become obsolete in clinical 4 practice. HCV TRI-DOT test is a rapid, protein A immunofiltration assay for the qualitative detection of anti HCV antibodies in serum or plasma with a sensitivity of 5 100% and specificity of 91.5%. In view of increasing prevalence of HCV in haemodialysis patients day by day, this study is taken to determine the seroprevalence of hepatitis-C infection in patients on haemodialysis in our institute and to assess the risk factors which lead to HCV infection in patients on haemodialysis. The present study 
DISCUSSION
Prevalence of anti-HCV antibody among hemodialysis (HD) patients is consistently higher than in general population indicating increased risk of acquiring HCV infection among HD patients. The reported incidence varies from country to country and depends upon type of assay used and execution trends for HD. HCV chronic infection causes significant morbidity and mortality among 6 patients undergoing HD. Currently, third-generation anti-HCV ELISA is largely in use and has shown greater 7 sensitivity and specificity in patients receiving HD. Fourth generation HCV TRI-DOT test is also in use for screening HCV infection with comparative sensitivity and specificity and less turn around time.
was designed to compare the effectiveness of two very important tests -3rd generation ELISA and 4th generation TRI-DOT test.
MATERIAL AND METHODS
Patient of age ≥ 18 yrs, chronic kidney disease / chronic renal failure and patients on haemodialysis for >2 months were included in the study.
After taking the approval of ethical committee of our institute, the work was started. Proper informed consent of patients was taken in dialysis unit and they were interviewed for history and their medical records reviewed to obtain details to include or exclude in study. Demographic data of all included patients reviewed for risk factors to HCV infection and biochemical parameters noted.
Three ml of blood sample withdrawn by venipuncture of 150 patients on haemodialysis from January 2015 to December 2015. Blood sample allowed to clot, sera was separated by centrifugation and tested by J. Mitra & Co. Pvt. Ltd. HCV TRI-DOT test, then by J. Mitra & Co. Pvt. Ltd HCV ELISA kit.
Statistical analysis was performed by the SPSS program for Windows, version 17.0 (SPSS, Chicago, Illinois). Continuous variables are presented as mean ± SD, and categorical variables are presented as absolute numbers and percentage. Data were checked for normality before statistical analysis. Normally distributed continuous variables were compared using the unpaired t test, whereas the Mann-Whitney U test was used for those variables that were not normally distributed. Categorical variables were analysed using either chi square test or Fisher's exact test.
RESULTS
Out of total 150 cases, 101 (67.3%) were males and 49 (32.7%) were females. Thirteen were in 18-25 years age group, 23 were in 26-35 years age group, 30 were in 36-45 years age group, 36 were in 46-55 years age group, 34 were in 56-65 years age group and 14 were in >65 years age group. It has been seen that maximum numbers of the renal patients fall in age group 36-65 yrs. Out of 150 cases, 17 cases were reactive and 133 cases were nonreactive by HCV TRI-DOT test. Sixteen cases found reactive and 134 cases were nonreactive by HCV ELISA test. Out of 16 reactive cases by HCV ELISA, 7 were females and 9 males. Twelve of 16 were fell in 36-55 years age group. (Fig.-1) Mean duration of haemodialysis is 21.52 ± 17.04 months in non reactive patients and 45.25 ± 26.21 months in reactive In present study, out of total 150 cases, 101(67.3%) were males and 49 (32.7%) were females, out of 16 reactive cases by HCV ELISA, 9 (56.3%) were males and 7 (43.8%) 7 were females which is similar to Jasuja S et al and 6 Khan S et al Maximum reactive cases fell in 36-45 years age group and followed by 46-55 years age group, similar is 8 3 seen in study of Covic A et al. and Hegde R et al
It revealed that as the duration of haemodialysis increases, the risk of developing HCV infection is enhanced. In this study, it has been observed that the mean duration in reactive cases is almost double of as in non reactive cases. 9 The study of Kamyar Kalantar-Zadeh et al and Jasuja S   7 et al stated that duration of HD was found to have significant impact on HCV positivity.
In this study difference between mean of dialysis centre changed in reactive and non reactive cases is almost twice. 7 10 Jasuja S et al and Megmar AS Carneiro et al showed that treatment in multiple units were significantly associated with HCV positivity.
As far as the seroprevalence of Hepatitis C is concerned in present study, it is 10.7% (16 patients were found positive for anti Hepatitis C antibodies by third generation HCV ELISA). On comparative statistical analysis, one sample which was non reactive by HCV ELISA but reactive by HCV TRI-DOT, considered as false positive due to decreased specificity of HCV TRI-DOT test. Kamyar 
CONCLUSION
Risk factors for HCV infection in haemodialysis patients included duration of haemodialysis, number of haemodialysis centre changed, number of blood unit transfused, male gender and middle age. In comparison of 3rd generation HCV ELISA, 4th generation HCV TRI-DOT test is rapid, easier to perform with less technical skills and less requirement of materials. The sensitivity of HCV TRI-DOT is equal to HCV ELISA but the specificity is slightly less.
